Largest Biotech Companies By Total Asset
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Total Asset
| Total Asset | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | REGN | Regeneron Pharmaceuticals | (0.40) | 1.72 | (0.69) | ||
| 2 | BNTX | BioNTech SE | 0.15 | 3.74 | 0.56 | ||
| 3 | IMAB | I Mab | (0.03) | 5.33 | (0.14) | ||
| 4 | DNA | Ginkgo Bioworks Holdings | 0.09 | 5.62 | 0.49 | ||
| 5 | ABCL | Abcellera Biologics | 0.06 | 3.99 | 0.23 | ||
| 6 | MRVI | Maravai Lifesciences Holdings | (0.07) | 6.19 | (0.44) | ||
| 7 | NUVL | Nuvalent | 0.07 | 4.37 | 0.29 | ||
| 8 | CPRX | Catalyst Pharmaceuticals | 0.09 | 1.92 | 0.17 | ||
| 9 | VALN | Valneva SE ADR | (0.36) | 2.58 | (0.92) | ||
| 10 | APGE | Apogee Therapeutics, Common | (0.04) | 3.45 | (0.15) | ||
| 11 | CNTA | Centessa Pharmaceuticals PLC | 0.13 | 3.88 | 0.49 | ||
| 12 | SYRE | Spyre Therapeutics | 0.00 | 3.67 | 0.01 | ||
| 13 | ABOS | Acumen Pharmaceuticals | (0.05) | 4.80 | (0.23) | ||
| 14 | INBX | Inhibrx | 0.04 | 3.20 | 0.14 | ||
| 15 | ARDX | Ardelyx | (0.01) | 4.51 | (0.02) | ||
| 16 | TCRX | Tscan Therapeutics | (0.06) | 3.71 | (0.24) | ||
| 17 | TARS | Tarsus Pharmaceuticals | 0.30 | 3.49 | 1.05 | ||
| 18 | CMRX | Chimerix | 0.00 | 3.20 | 0.00 | ||
| 19 | SMMT | Summit Therapeutics PLC | 0.10 | 9.60 | 0.98 | ||
| 20 | MOLN | Molecular Partners AG | 0.04 | 7.07 | 0.26 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.